|
Search
Collections
Benchmarks
Upload document
Indication
MET Activating Mutation
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 product
Clinical trial
Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)
Status: Recruiting
, Estimated PCD: 2024-12-01
Product
Crizotinib
